Cargando…
Hydroxychloroquine and COVID-19 – A narrative review
COVID 19 infection is unarguably the worst pandemic of this century. Till date there is no promising drug and vaccine available to treat this deadly viral infection. In the early phase chloroquine phosphate and hydroxychloroquine sulphate have been used to fight this illness on the basis of handful...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V. on behalf of Tuberculosis Association of India.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836863/ https://www.ncbi.nlm.nih.gov/pubmed/33308661 http://dx.doi.org/10.1016/j.ijtb.2020.06.004 |
_version_ | 1783642837056749568 |
---|---|
author | Bajpai, Jyoti Pradhan, Akshyaya Singh, Abhishek kant, Surya |
author_facet | Bajpai, Jyoti Pradhan, Akshyaya Singh, Abhishek kant, Surya |
author_sort | Bajpai, Jyoti |
collection | PubMed |
description | COVID 19 infection is unarguably the worst pandemic of this century. Till date there is no promising drug and vaccine available to treat this deadly viral infection. In the early phase chloroquine phosphate and hydroxychloroquine sulphate have been used to fight this illness on the basis of handful observational and small randomized and small-randomized studies. The paucity of clinical evidences of an unequivocal beneficial effect of chloroquine and hydroxychloroquine on COVID-19 has resulted in the passionate use of the drug for moderate to severe cases only and stimulated the need for large clinical trials for this and other molecules. In this review, we describe in brief the mechanism of action, the clinical studies, factors for cardiac toxicity, guidelines and future directions for hydroxychloroquine use in management of COVID-19 infection. |
format | Online Article Text |
id | pubmed-7836863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier B.V. on behalf of Tuberculosis Association of India. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78368632021-01-26 Hydroxychloroquine and COVID-19 – A narrative review Bajpai, Jyoti Pradhan, Akshyaya Singh, Abhishek kant, Surya Indian J Tuberc Review Article COVID 19 infection is unarguably the worst pandemic of this century. Till date there is no promising drug and vaccine available to treat this deadly viral infection. In the early phase chloroquine phosphate and hydroxychloroquine sulphate have been used to fight this illness on the basis of handful observational and small randomized and small-randomized studies. The paucity of clinical evidences of an unequivocal beneficial effect of chloroquine and hydroxychloroquine on COVID-19 has resulted in the passionate use of the drug for moderate to severe cases only and stimulated the need for large clinical trials for this and other molecules. In this review, we describe in brief the mechanism of action, the clinical studies, factors for cardiac toxicity, guidelines and future directions for hydroxychloroquine use in management of COVID-19 infection. Published by Elsevier B.V. on behalf of Tuberculosis Association of India. 2020-12 2020-07-03 /pmc/articles/PMC7836863/ /pubmed/33308661 http://dx.doi.org/10.1016/j.ijtb.2020.06.004 Text en © 2020 Published by Elsevier B.V. on behalf of Tuberculosis Association of India. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Bajpai, Jyoti Pradhan, Akshyaya Singh, Abhishek kant, Surya Hydroxychloroquine and COVID-19 – A narrative review |
title | Hydroxychloroquine and COVID-19 – A narrative review |
title_full | Hydroxychloroquine and COVID-19 – A narrative review |
title_fullStr | Hydroxychloroquine and COVID-19 – A narrative review |
title_full_unstemmed | Hydroxychloroquine and COVID-19 – A narrative review |
title_short | Hydroxychloroquine and COVID-19 – A narrative review |
title_sort | hydroxychloroquine and covid-19 – a narrative review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836863/ https://www.ncbi.nlm.nih.gov/pubmed/33308661 http://dx.doi.org/10.1016/j.ijtb.2020.06.004 |
work_keys_str_mv | AT bajpaijyoti hydroxychloroquineandcovid19anarrativereview AT pradhanakshyaya hydroxychloroquineandcovid19anarrativereview AT singhabhishek hydroxychloroquineandcovid19anarrativereview AT kantsurya hydroxychloroquineandcovid19anarrativereview |